Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies
In treating locally advanced esophageal carcinoma, neoadjuvant therapy followed by surgery represents a key approach. However, the timing of surgery following neoadjuvant therapy in esophageal carcinoma remains controversial.
We conducted a syst...
Jian-Feng Zhou, Pin-Hao Fang, Yong Yuan et al.· Diseases of the esophagus· 0 citations
Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies
The integration of anti-PD-1 antibody therapy with chemotherapy has shown promising results in the neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma. Conventional imaging may not fully capture immunotherapy effects due to unc...
Jian-Feng Zhou, Yu-Shang Yang, Yong Yuan et al.· Diseases of the esophagus· 0 citations
BACKGROUND
Gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and esophageal adenocarcinoma (EAC) form a recognized pathological continuum, but the causal immune and inflammatory processes driving progression remain incompletely defined.
METHODS
Summary-level genome-wide association study (GWAS) data w...
Yixin Liu, Zhipeng Gong, Yuwen Tan et al.· Journal of Translational Med...· 0 citations
Neoadjuvant immunochemotherapy (nICT) has emerged as a promising neoadjuvant strategy for esophageal squamous cell carcinoma (ESCC). Identification of the factors affecting the responsiveness to nICT could help further improve treatment efficacy. Here, we performed single-cell analysis on 14 ESCC patients undergoing nI...
Linyan Chen, Tang Feng, Jianfeng Zhou et al.· Cancer Research· 1 citation
FGF19 emerges as a key cytokine driving EGJ glandular remodeling through HLA-DR+ CD4+/CD8+ T-cell associated immune activation, providing candidate molecular targets for early prevention and intervention.
Yixin Liu, Jianfeng Zhou, Yushang Yang et al.· Diseases of the esophagus· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
